 Robert Mcduffie
Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications, Infectious | 13 | 2004 | 285 | 0.860 |
Why?
| | Escherichia coli Infections | 9 | 2002 | 102 | 0.740 |
Why?
| | Streptococcus agalactiae | 5 | 1999 | 81 | 0.410 |
Why?
| | Streptococcal Infections | 5 | 1999 | 127 | 0.390 |
Why?
| | Pregnancy | 32 | 2014 | 5499 | 0.360 |
Why?
| | Sulbactam | 5 | 2002 | 5 | 0.340 |
Why?
| | Ampicillin | 5 | 2002 | 13 | 0.340 |
Why?
| | Amniotic Fluid | 6 | 2002 | 64 | 0.330 |
Why?
| | Prenatal Care | 4 | 2004 | 250 | 0.330 |
Why?
| | Pregnancy Outcome | 5 | 2014 | 337 | 0.320 |
Why?
| | Fetal Diseases | 3 | 2002 | 146 | 0.300 |
Why?
| | Postpartum Hemorrhage | 1 | 2007 | 13 | 0.280 |
Why?
| | Balloon Occlusion | 1 | 2007 | 23 | 0.280 |
Why?
| | Rabbits | 13 | 2004 | 733 | 0.270 |
Why?
| | Catheterization | 1 | 2007 | 158 | 0.270 |
Why?
| | Office Visits | 2 | 1997 | 79 | 0.270 |
Why?
| | Diabetes, Gestational | 4 | 2012 | 281 | 0.250 |
Why?
| | alpha-Fetoproteins | 2 | 1996 | 31 | 0.250 |
Why?
| | Bacteremia | 3 | 1999 | 160 | 0.230 |
Why?
| | Fetal Membranes, Premature Rupture | 2 | 1993 | 34 | 0.200 |
Why?
| | Sialoglycoproteins | 2 | 2001 | 158 | 0.190 |
Why?
| | Weight Gain | 2 | 2014 | 453 | 0.170 |
Why?
| | Pregnancy Complications | 2 | 2014 | 430 | 0.170 |
Why?
| | Escherichia coli | 3 | 2002 | 723 | 0.170 |
Why?
| | Receptors, Interleukin-1 | 1 | 2001 | 228 | 0.170 |
Why?
| | Pregnancy, Multiple | 1 | 1999 | 14 | 0.160 |
Why?
| | Meconium | 1 | 1999 | 7 | 0.160 |
Why?
| | Breast Diseases | 1 | 1999 | 20 | 0.160 |
Why?
| | Hepatitis A | 1 | 1999 | 26 | 0.160 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 1999 | 51 | 0.160 |
Why?
| | Puerperal Infection | 1 | 1998 | 4 | 0.150 |
Why?
| | Peritonitis | 1 | 1999 | 77 | 0.150 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1999 | 70 | 0.150 |
Why?
| | Levofloxacin | 1 | 1998 | 22 | 0.150 |
Why?
| | Ofloxacin | 1 | 1998 | 22 | 0.150 |
Why?
| | Adiposity | 3 | 2013 | 458 | 0.150 |
Why?
| | Breast Feeding | 2 | 2012 | 366 | 0.150 |
Why?
| | Female | 34 | 2014 | 59325 | 0.140 |
Why?
| | Trisomy | 2 | 1996 | 68 | 0.140 |
Why?
| | Fetal Death | 3 | 2002 | 50 | 0.140 |
Why?
| | Health Services | 1 | 1997 | 103 | 0.130 |
Why?
| | Genital Diseases, Female | 1 | 1996 | 25 | 0.130 |
Why?
| | Estriol | 1 | 1996 | 5 | 0.130 |
Why?
| | Ultrasonography, Prenatal | 2 | 1996 | 237 | 0.130 |
Why?
| | Obesity | 3 | 2014 | 2505 | 0.130 |
Why?
| | Chorionic Gonadotropin | 1 | 1996 | 78 | 0.130 |
Why?
| | Anti-Infective Agents | 1 | 1998 | 219 | 0.130 |
Why?
| | Pregnancy Trimester, Second | 2 | 1994 | 66 | 0.120 |
Why?
| | Aztreonam | 1 | 1995 | 8 | 0.120 |
Why?
| | Amnion | 1 | 1995 | 24 | 0.120 |
Why?
| | Drug Therapy, Combination | 5 | 2002 | 949 | 0.120 |
Why?
| | Gentamicins | 1 | 1995 | 42 | 0.120 |
Why?
| | Hemoperitoneum | 1 | 1994 | 12 | 0.120 |
Why?
| | Prenatal Diagnosis | 1 | 1996 | 163 | 0.120 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 1994 | 42 | 0.110 |
Why?
| | Placenta Accreta | 1 | 1994 | 24 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2001 | 1128 | 0.110 |
Why?
| | Ampicillin Resistance | 1 | 1993 | 1 | 0.110 |
Why?
| | Subcutaneous Fat | 1 | 2014 | 70 | 0.110 |
Why?
| | Amoxicillin | 1 | 1993 | 20 | 0.110 |
Why?
| | Klebsiella Infections | 1 | 1993 | 23 | 0.110 |
Why?
| | Klebsiella pneumoniae | 1 | 1993 | 41 | 0.110 |
Why?
| | Infant, Newborn | 10 | 2012 | 5038 | 0.110 |
Why?
| | Abortion, Veterinary | 1 | 1992 | 1 | 0.110 |
Why?
| | Uterus | 5 | 2007 | 191 | 0.110 |
Why?
| | Adolescent Development | 1 | 2013 | 83 | 0.100 |
Why?
| | Hyperinsulinism | 1 | 2013 | 103 | 0.100 |
Why?
| | Abnormalities, Multiple | 1 | 1994 | 176 | 0.100 |
Why?
| | Adiponectin | 1 | 2013 | 213 | 0.100 |
Why?
| | Thiazolidinediones | 1 | 2013 | 142 | 0.100 |
Why?
| | Cervix Uteri | 1 | 1992 | 44 | 0.100 |
Why?
| | Child of Impaired Parents | 1 | 2012 | 40 | 0.100 |
Why?
| | Uterine Diseases | 2 | 2002 | 14 | 0.090 |
Why?
| | Down Syndrome | 1 | 1996 | 335 | 0.090 |
Why?
| | Down-Regulation | 1 | 2013 | 594 | 0.090 |
Why?
| | Body Mass Index | 3 | 2014 | 1957 | 0.090 |
Why?
| | Cesarean Section | 2 | 2007 | 169 | 0.090 |
Why?
| | Pregnancy in Diabetics | 1 | 2012 | 82 | 0.090 |
Why?
| | Physical Examination | 1 | 1992 | 221 | 0.090 |
Why?
| | Islets of Langerhans | 1 | 1996 | 728 | 0.090 |
Why?
| | Disease Models, Animal | 6 | 2004 | 3498 | 0.080 |
Why?
| | Child Development | 1 | 2013 | 384 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 1999 | 1331 | 0.080 |
Why?
| | Adult | 12 | 2014 | 30375 | 0.080 |
Why?
| | Fetal Growth Retardation | 1 | 2013 | 470 | 0.080 |
Why?
| | Interleukin-1 | 1 | 1992 | 965 | 0.080 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2004 | 3254 | 0.070 |
Why?
| | Humans | 24 | 2014 | 114043 | 0.070 |
Why?
| | Maternal Age | 2 | 2005 | 116 | 0.070 |
Why?
| | Mass Screening | 4 | 2005 | 979 | 0.070 |
Why?
| | Fetus | 3 | 2002 | 698 | 0.070 |
Why?
| | Animals | 13 | 2004 | 31565 | 0.070 |
Why?
| | Hysterectomy | 1 | 2007 | 105 | 0.070 |
Why?
| | Health Maintenance Organizations | 2 | 1996 | 93 | 0.060 |
Why?
| | Insulin Resistance | 1 | 2013 | 1072 | 0.060 |
Why?
| | Embolization, Therapeutic | 1 | 2007 | 178 | 0.060 |
Why?
| | Arteries | 1 | 2007 | 246 | 0.060 |
Why?
| | Bacteroidaceae Infections | 1 | 2004 | 4 | 0.060 |
Why?
| | Prevotella | 1 | 2004 | 12 | 0.060 |
Why?
| | Obstetric Labor, Premature | 1 | 2004 | 33 | 0.060 |
Why?
| | Time Factors | 5 | 2013 | 6077 | 0.060 |
Why?
| | Waist Circumference | 2 | 2014 | 122 | 0.050 |
Why?
| | Delivery, Obstetric | 1 | 2004 | 118 | 0.050 |
Why?
| | Random Allocation | 2 | 2001 | 328 | 0.050 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2001 | 253 | 0.050 |
Why?
| | Cohort Studies | 5 | 2013 | 4883 | 0.050 |
Why?
| | Adolescent | 5 | 2013 | 17800 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 1726 | 0.050 |
Why?
| | Colorado | 5 | 2013 | 4090 | 0.050 |
Why?
| | Risk | 2 | 2013 | 810 | 0.040 |
Why?
| | Dinoprostone | 1 | 2001 | 183 | 0.040 |
Why?
| | Body Temperature | 1 | 2001 | 208 | 0.040 |
Why?
| | Tetanus Toxoid | 1 | 1999 | 37 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 2087 | 0.040 |
Why?
| | Polysaccharides, Bacterial | 1 | 1999 | 66 | 0.040 |
Why?
| | Bacterial Vaccines | 1 | 1999 | 61 | 0.040 |
Why?
| | Ascites | 1 | 1999 | 32 | 0.040 |
Why?
| | Autoimmunity | 1 | 2004 | 812 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1999 | 281 | 0.040 |
Why?
| | Animals, Newborn | 2 | 1999 | 777 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2002 | 714 | 0.040 |
Why?
| | Twins | 1 | 1999 | 240 | 0.040 |
Why?
| | Fetal Movement | 1 | 1997 | 6 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2013 | 2764 | 0.040 |
Why?
| | Fetal Monitoring | 1 | 1997 | 16 | 0.040 |
Why?
| | Child | 5 | 2014 | 18400 | 0.030 |
Why?
| | Genotype | 2 | 2004 | 1757 | 0.030 |
Why?
| | Oropharynx | 1 | 1996 | 36 | 0.030 |
Why?
| | Amniocentesis | 1 | 1996 | 21 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 1996 | 44 | 0.030 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 1996 | 10 | 0.030 |
Why?
| | Histocompatibility Testing | 1 | 1996 | 115 | 0.030 |
Why?
| | Karyotyping | 1 | 1996 | 100 | 0.030 |
Why?
| | Administration, Oral | 1 | 1998 | 725 | 0.030 |
Why?
| | Glutamate Decarboxylase | 1 | 1996 | 160 | 0.030 |
Why?
| | Acoustic Stimulation | 1 | 1997 | 306 | 0.030 |
Why?
| | Ultrasonography | 1 | 1999 | 635 | 0.030 |
Why?
| | Insulin Antibodies | 1 | 1996 | 102 | 0.030 |
Why?
| | Genetic Counseling | 1 | 1996 | 65 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 1996 | 134 | 0.030 |
Why?
| | HLA-DQ Antigens | 1 | 1996 | 174 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 1996 | 124 | 0.030 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 1996 | 147 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2011 | 453 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 1996 | 219 | 0.030 |
Why?
| | HLA Antigens | 1 | 1996 | 220 | 0.030 |
Why?
| | Male | 8 | 2014 | 55396 | 0.030 |
Why?
| | Endometrium | 1 | 1995 | 60 | 0.030 |
Why?
| | Dandy-Walker Syndrome | 1 | 1994 | 7 | 0.030 |
Why?
| | Pre-Eclampsia | 1 | 1996 | 166 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2014 | 184 | 0.030 |
Why?
| | Indomethacin | 1 | 1993 | 70 | 0.030 |
Why?
| | Alleles | 1 | 1996 | 789 | 0.030 |
Why?
| | Antithrombin III Deficiency | 1 | 1993 | 3 | 0.030 |
Why?
| | Subclavian Vein | 1 | 1993 | 14 | 0.030 |
Why?
| | Abdominal Fat | 1 | 2013 | 39 | 0.030 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 1993 | 16 | 0.030 |
Why?
| | Chorioamnionitis | 1 | 1993 | 36 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 1996 | 381 | 0.030 |
Why?
| | Risk Factors | 4 | 2004 | 8614 | 0.030 |
Why?
| | Fetal Blood | 3 | 2004 | 268 | 0.030 |
Why?
| | Sulfonylurea Compounds | 1 | 2013 | 44 | 0.030 |
Why?
| | Cytokines | 1 | 2000 | 1824 | 0.030 |
Why?
| | Warfarin | 1 | 1993 | 136 | 0.020 |
Why?
| | Infant, Premature | 1 | 1996 | 478 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 1996 | 571 | 0.020 |
Why?
| | Pregnancy Trimester, Third | 1 | 1992 | 79 | 0.020 |
Why?
| | Retrospective Studies | 3 | 2013 | 12521 | 0.020 |
Why?
| | Prospective Studies | 3 | 2014 | 6195 | 0.020 |
Why?
| | Infant | 2 | 2012 | 7943 | 0.020 |
Why?
| | Injections, Intramuscular | 1 | 1991 | 117 | 0.020 |
Why?
| | Progesterone | 1 | 1991 | 232 | 0.020 |
Why?
| | Anti-Bacterial Agents | 2 | 1996 | 1471 | 0.020 |
Why?
| | Obstetrics | 1 | 1992 | 146 | 0.020 |
Why?
| | Thrombosis | 1 | 1993 | 295 | 0.020 |
Why?
| | Metformin | 1 | 2013 | 274 | 0.020 |
Why?
| | Biomarkers | 2 | 1996 | 3397 | 0.020 |
Why?
| | Autoantibodies | 1 | 1996 | 1347 | 0.020 |
Why?
| | Algorithms | 1 | 1994 | 1469 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2384 | 0.020 |
Why?
| | Placenta | 2 | 2000 | 628 | 0.010 |
Why?
| | Birth Order | 1 | 2004 | 12 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2004 | 302 | 0.010 |
Why?
| | Regression Analysis | 1 | 2005 | 945 | 0.010 |
Why?
| | Treatment Failure | 1 | 2002 | 330 | 0.010 |
Why?
| | Opsonin Proteins | 1 | 1999 | 25 | 0.010 |
Why?
| | Peritoneum | 1 | 1999 | 36 | 0.010 |
Why?
| | Vaccines, Conjugate | 1 | 1999 | 59 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1999 | 159 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1999 | 119 | 0.010 |
Why?
| | Child, Preschool | 1 | 2012 | 9114 | 0.010 |
Why?
| | Acute Disease | 1 | 2000 | 907 | 0.010 |
Why?
| | Palpation | 1 | 1997 | 12 | 0.010 |
Why?
| | Gestational Age | 1 | 1999 | 761 | 0.010 |
Why?
| | NF-kappa B | 1 | 2000 | 636 | 0.010 |
Why?
| | Quality Control | 1 | 1996 | 143 | 0.010 |
Why?
| | Chronic Disease | 1 | 2002 | 1577 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1999 | 766 | 0.010 |
Why?
| | DNA Primers | 1 | 1996 | 508 | 0.010 |
Why?
| | Uterine Cervical Diseases | 1 | 1993 | 6 | 0.010 |
Why?
| | Premedication | 1 | 1993 | 36 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1996 | 990 | 0.010 |
Why?
| | Contraindications | 1 | 1993 | 84 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 4595 | 0.010 |
Why?
| | Patient Compliance | 1 | 1996 | 524 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1994 | 735 | 0.010 |
Why?
| | Inflammation | 1 | 2002 | 2464 | 0.010 |
Why?
| | Incidence | 1 | 1996 | 2314 | 0.010 |
Why?
| | Lung | 1 | 2000 | 3521 | 0.000 |
Why?
| | Follow-Up Studies | 1 | 1996 | 4392 | 0.000 |
Why?
| | Treatment Outcome | 1 | 1993 | 9049 | 0.000 |
Why?
|
|
Mcduffie's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|